Literature DB >> 19774788

Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease.

Estelle Leclerc1, Emmanuel Sturchler, Stefan W Vetter, Claus W Heizmann.   

Abstract

Hallmarks of Alzheimer's disease (AD) include the accumulation of amyloid beta peptide (Abeta), hyperphosphorylation of tau protein, and increased inflammatory activity in the hippocampus and cerebral cortex. The receptor for advanced glycation endproducts (RAGE) has been shown to interact with Abeta and to modulate Abeta transport across the blood-brain barrier. Furthermore, RAGE is upregulated at sites of inflammation and its activation results in distinct intracellular signaling cascades in respect to Abeta conformers. Besides Abeta, RAGE interacts with several members of the calcium binding S100 protein family, amphoterin and advanced glycation endproducts. Mounting evidence suggests that RAGE is a key player in the signaling pathways triggered by Abeta and S100 proteins in AD. In this review, we discuss recent discoveries about the crosstalk between RAGE, Abeta and S100 proteins in the pathophysiology of AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19774788     DOI: 10.1515/revneuro.2009.20.2.95

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  7 in total

1.  Genetic association of sequence variants near AGER/NOTCH4 and dementia.

Authors:  Anna M Bennet; Chandra A Reynolds; Ulrika K Eriksson; Mun-Gwan Hong; Kaj Blennow; Margaret Gatz; Andrey Alexeyenko; Nancy L Pedersen; Jonathan A Prince
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

2.  Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE.

Authors:  Roberto Romero; Tinnakorn Chaiworapongsa; Zeynep Alpay Savasan; Youssef Hussein; Zhong Dong; Juan Pedro Kusanovic; Chong Jai Kim; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2012-06

3.  Clinical aspects of melatonin intervention in Alzheimer's disease progression.

Authors:  Daniel P Cardinali; Analía M Furio; Luis I Brusco
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

4.  Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress.

Authors:  Alexander Kurz; Naila Rabbani; Michael Walter; Michael Bonin; Paul Thornalley; Georg Auburger; Suzana Gispert
Journal:  Cell Mol Life Sci       Date:  2010-08-14       Impact factor: 9.261

5.  TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding.

Authors:  Masakiyo Sakaguchi; Hitoshi Murata; Ken-ichi Yamamoto; Tomoyuki Ono; Yoshihiko Sakaguchi; Akira Motoyama; Toshihiko Hibino; Ken Kataoka; Nam-ho Huh
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

6.  Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Bo-Ryoung Choi; Woo-Hyun Cho; Jiyoung Kim; Hyong Joo Lee; ChiHye Chung; Won Kyung Jeon; Jung-Soo Han
Journal:  Exp Mol Med       Date:  2014-02-07       Impact factor: 8.718

7.  HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition.

Authors:  Xiaorong Luan; Chunjing Ma; Ping Wang; Fenglan Lou
Journal:  Onco Targets Ther       Date:  2017-03-03       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.